Legal and Economic Perspectives Concerning US Government Investigations of Alleged Off-Label Promotion by Drug Manufacturers Paul E. KalbPaul E. Greenberg Editorial 17 September 2012 Pages: 623 - 625
Case-Control Studies in Pharmacoeconomic Research J. Jaime CaroKrista F. Huybrechts Leading Article 17 September 2012 Pages: 627 - 634
Estimating Drug Costs in Economic Evaluations in Ireland and the UK Dyfrig A. HughesLesley TilsonMichael Drummond Leading Article 17 September 2012 Pages: 635 - 643
A Decision-Theoretic Framework for the Application of Cost-Effectiveness Analysis in Regulatory Processes Gianluca BaioPierluigi Russo Leading Article 17 September 2012 Pages: 645 - 655
Economic Burden of Follicular Non-Hodgkin’s Lymphoma Talia FosterJeffrey D. MillerMason W. Russell Review Article 17 September 2012 Pages: 657 - 679
The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US Jasmina I. IvanovaHoward G. BirnbaumDennis Meletiche Original Research Article 17 September 2012 Pages: 681 - 691
Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women Andrej RaschJan-Marc HodekWolfgang Greiner Original Research Article 17 September 2012 Pages: 693 - 704